Last reviewed · How we verify
NCT03546634
Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China
Phase 4 trial testing Sabin IPV in Poliomyelitis in 280 participants. Completed in 15 January 2020.
5 June 2019
Quick facts
| Lead sponsor | Centers for Disease Control and Prevention, China |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 280 |
| Start date | 24 May 2018 |
| Primary completion | 5 June 2019 |
| Estimated completion | 15 January 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sabin IPV — full drug profile →
Conditions studied
- Poliomyelitis — all drugs for Poliomyelitis →
Sponsor
Centers for Disease Control and Prevention, China — full company profile →
Who can join
Adults 2 Months to 18 Months, any sex, with Poliomyelitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to obtain the direct domestic IPV vaccine monitoring data for the CNBG products, and provide scientific evidence for the National Immunization Program and long-term polio vaccine immunization policy. The overall objective of this research is to determine the seroconversion rates of two reduced Sabin IPV schedules in Chinese children - a 2-dose schedule and a 3-dose schedule.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03546634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sabin IPV
Trials testing the same drug.
- NCT03597919 — A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. · Phase 4 · completed
Other recruiting trials for Poliomyelitis
Currently open trials in the same condition.
- NCT07457060 — Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine · Phase 4 · recruiting
- NCT06895486 — Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation · Phase 2 · recruiting
- NCT07354269 — Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations · Phase 4 · recruiting
- NCT06137664 — Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines · Phase 1, PHASE2 · recruiting
- NCT05644184 — Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh · Phase 2 · recruiting
Other Centers for Disease Control and Prevention, China trials
Trials by the same sponsor.
- NCT05298800 — Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 · Phase 4 · unknown
- NCT04614597 — A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China · completed
- NCT05087277 — Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain · unknown
- NCT05072496 — Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine · completed
- NCT03597919 — A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03546634 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centers for Disease Control and Prevention, China
- Last refreshed: 24 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03546634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing